Search Orphan Drug Designations and Approvals
-
| Generic Name: | gilteritinib |
|---|---|
| Trade Name: | XOSPATA |
| Date Designated: | 07/13/2017 |
| Orphan Designation: | Treatment of acute myeloid leukemia (AML) |
| Orphan Designation Status: | Designated/Approved |
| Marketing Approval Date: | 11/28/2018 |
| Approved Labeled Indication: | XOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test. |
| Exclusivity End Date: | 11/28/2025 |
| Exclusivity Protected Indication* : | XOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test. |
| Sponsor: |
Astellas Pharma US, Inc. 1 Astellas Way Northbrook, Illinois 60062 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
-
